Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice

Area of Science:

• Genetics
• Pharmacology
• Clinical Medicine

Background:

• Interindividual variability in drug response is a significant clinical challenge.
• Genetic variations in drug-metabolizing enzymes, transporters, and receptors influence pharmacokinetics (PKs) and pharmacodynamics (PDs).

Purpose of the Study:

• To discuss the challenges and emerging technologies in pharmacogenomics (PGx) biomarker discovery and validation.
• To highlight the integration of molecular genetics, bioinformatics, and clinical medicine for optimizing tailored drug therapy.

Main Methods:

• Review of high-throughput PGx genotyping strategies for identifying PK/PD genotypes.
• Discussion of the validation process, clinical-grade assay development, and regulatory compliance for biomarkers.

Main Results:

• Pharmacogenomics enables the identification of predictive biomarkers for drug PKs and PDs.
• Knowledge of genome-drug interactions facilitates personalized medicine approaches.

Conclusions:

• Robust validation and regulatory adherence are crucial for clinical implementation of PGx biomarkers.
• Technological advancements are aiding PGx biomarker discovery and validation, bridging genetics, bioinformatics, and clinical practice.